HHS and VA Launch Psychedelic Therapy Partnership for Veterans

The federal government has begun building the clinical machinery to deliver psychedelic therapies to veterans — training clinicians, drafting treatment protocols, and standing up data systems — well before any such treatment has cleared the Food and Drug Administration.

On July 13, 2026, the Department of Health and Human Services and the Department of Veterans Affairs signed a five-year agreement to coordinate their work on rapid-acting mental health treatments, including psychedelic drugs, for veterans living with serious mental illness. The deal does not put any psychedelic on the shelf at the VA today. It commits the two departments to get the health system ready so that, if a treatment wins approval, the VA can offer it without the long lag that usually follows an FDA decision.

That readiness-first framing is the heart of the agreement. The departments say they will train therapists, nurses and physicians to administer future approved treatments, develop clinical protocols, and collect real-world data on safety, effectiveness and cost. A second, complementary agreement between the FDA and the VA covers information sharing and scientific collaboration aimed at speeding the development and review of these therapies. HHS Secretary Robert F. Kennedy Jr. said the departments were not willing to wait while promising treatments sit on the sidelines, and VA Secretary Doug Collins framed the pact as turning research into treatment.

The partnership carries out Executive Order 14401, which President Trump signed in April 2026 and which directed HHS, the FDA and the VA to increase clinical-trial participation and share data with an eye toward faster approvals.

Why veterans are the focus

The order that set this in motion pointed to a stark gap in care. More than 14 million American adults live with a serious mental illness, and standard medication and psychotherapy do not fully help everyone. Veterans carry a heavier share of that burden: the order noted that more than 6,000 veterans have died by suicide each year for over two decades, at a rate more than double that of other adults. Those numbers are why officials describe psychedelics — under study for treatment-resistant depression, post-traumatic stress disorder and substance use disorders — as worth pursuing while the evidence is still maturing.

The VA is already one of the most active players in this research. The department says it is running 20 clinical trials on psychedelic therapies, supported by its Office of Research and Development and more than $23 million in outside funding. That work includes a recently launched MDMA-assisted therapy trial for veterans with PTSD and alcohol use disorder. The VA has long stressed that its psychedelic research runs under strict safety protocols and that it discourages veterans from self-medicating outside a clinical setting — a message that also runs through the longer debate over veterans’ access to cannabis for PTSD.

What the evidence does and doesn’t show

Here the wellness-curious reader deserves a plain line: no psychedelic drug has been approved by the FDA for any psychiatric condition. The agency declined to approve the first such application — MDMA-assisted therapy for PTSD — in 2024, citing problems with how the trials were designed. Several psychedelics, including MDMA and psilocybin, hold Breakthrough Therapy status, which lets the FDA speed its review but does not lower the standard of proof a drug must meet.

Federal officials were unusually candid about the limits of the science. NIH Director Jay Bhattacharya said there is “preliminary evidence that psychedelic therapies can rewire the brain and produce rapid improvements for people with serious mental illness or substance use disorders,” but added that “we still have much to learn about long-term benefits and risks, including the potential for misuse.”

The FDA underscored the same caution in final guidance issued the same day, which lays out the unique challenges of studying drugs that cause intense changes in perception lasting hours. Chief among them is functional unblinding: patients and clinicians can usually tell who received the active drug rather than a placebo, which makes it hard to separate a real treatment effect from expectation. The guidance, which finalizes a draft first proposed in 2023, also presses drug developers to show that any benefit lasts.

A wider federal push

The agreement arrived alongside a cluster of related actions. The National Institute on Drug Abuse, which has studied ibogaine for decades, awarded funding for a multi-phase project to support an investigational new drug application for the compound as a treatment for opioid use disorder. That work carries a specific safety flag: earlier studies found ibogaine can trigger dangerous heart-rhythm problems, and the new research is meant to test whether revised dosing can reduce that risk while preserving any benefit. HHS’s Advanced Research Projects Agency for Health opened a separate funding competition on ibogaine, and its Health Resources and Services Administration asked clinicians and health centers — including rural and community behavioral health providers — for input on how to deliver these therapies safely if they are ever approved. The interest in psychedelics for addiction echoes findings from earlier work, such as a study on psilocybin-assisted therapy for cocaine dependence.

The FDA also scheduled a public hearing for September 14, 2026 to gather input on how psychedelic drugs might be used in supervised, supportive settings.

What to watch

For veterans and the clinicians who field their questions, the practical message is preparation, not availability. Nothing in the agreement shortcuts the FDA’s approval standard; it shortens the distance between an approval and a veteran actually receiving care. Whether that distance ever closes depends on trials still underway — and on long-term safety and durability data that, by the government’s own account, is not yet in. Public support for regulated psychedelic therapy has climbed sharply in recent years, but sentiment is not evidence, and the coming year of trial readouts and the FDA’s September hearing will do more to settle the question than any memorandum.